Wang DS - Search Results

1

Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.

Lu Q, Wang DS, Chen CS, Hu YD, Chen CS. Lu Q, et al. Among authors: wang ds. J Med Chem. 2005 Aug 25;48(17):5530-5. doi: 10.1021/jm0503749. J Med Chem. 2005. PMID: 16107152

2

alpha-Tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 function.

Shiau CW, Huang JW, Wang DS, Weng JR, Yang CC, Lin CH, Li C, Chen CS. Shiau CW, et al. Among authors: wang ds. J Biol Chem. 2006 Apr 28;281(17):11819-25. doi: 10.1074/jbc.M511015200. Epub 2006 Mar 6. J Biol Chem. 2006. PMID: 16520381 Free article.

3

Development of small-molecule cyclin D1-ablative agents.

Huang JW, Shiau CW, Yang J, Wang DS, Chiu HC, Chen CY, Chen CS. Huang JW, et al. Among authors: wang ds. J Med Chem. 2006 Jul 27;49(15):4684-9. doi: 10.1021/jm060057h. J Med Chem. 2006. PMID: 16854074

4

Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.

Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS. Kulp SK, et al. Among authors: wang ds. Clin Cancer Res. 2006 Sep 1;12(17):5199-206. doi: 10.1158/1078-0432.CCR-06-0429. Clin Cancer Res. 2006. Retraction in: Clin Cancer Res. 2019 May 1;25(9):2940. doi: 10.1158/1078-0432.CCR-19-0731 PMID: 16951239 Retracted.

5

Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.

Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL, Chen CS. Lu YS, et al. Hepatology. 2007 Oct;46(4):1119-30. doi: 10.1002/hep.21804. Hepatology. 2007. PMID: 17654699

6

A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells.

Weng JR, Tsai CH, Kulp SK, Wang D, Lin CH, Yang HC, Ma Y, Sargeant A, Chiu CF, Tsai MH, Chen CS. Weng JR, et al. Cancer Res. 2007 Aug 15;67(16):7815-24. doi: 10.1158/0008-5472.CAN-07-0794. Cancer Res. 2007. PMID: 17699787

7

FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling.

Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK, Muthusamy N, Byrd JC, Cheng AL, Chen CS. Hung JH, et al. Among authors: wang ds, wang yc. Cancer Res. 2008 Feb 15;68(4):1204-12. doi: 10.1158/0008-5472.CAN-07-2621. Cancer Res. 2008. PMID: 18281497

8

Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents.

Yang J, Wei S, Wang DS, Wang YC, Kulp SK, Chen CS. Yang J, et al. Among authors: wang ds, wang yc. J Med Chem. 2008 Apr 10;51(7):2100-7. doi: 10.1021/jm701212m. Epub 2008 Mar 13. J Med Chem. 2008. PMID: 18335975 Free PMC article.

9

Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.

Wang YC, Kulp SK, Wang D, Yang CC, Sargeant AM, Hung JH, Kashida Y, Yamaguchi M, Chang GD, Chen CS. Wang YC, et al. Cancer Res. 2008 Apr 15;68(8):2820-30. doi: 10.1158/0008-5472.CAN-07-1336. Cancer Res. 2008. PMID: 18413750 Free PMC article.

10

Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.

Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS. Weng SC, et al. Mol Cancer Ther. 2008 Apr;7(4):800-8. doi: 10.1158/1535-7163.MCT-07-0434. Mol Cancer Ther. 2008. Retraction in: Mol Cancer Ther. 2019 Apr;18(4):869. doi: 10.1158/1535-7163.MCT-19-0151 PMID: 18413793 Retracted.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,079 results

Search Page

Filters